Posterior Reversible Encephalopathy Syndrome Following Chemotherapy and Immune Checkpoint Inhibitor Combination in a Patient with Small-Cell Lung Cancer

被引:3
|
作者
Evin, Cecile [1 ]
Lassau, Nathalie [1 ,2 ]
Balleyguier, Corinne [1 ,2 ]
Assi, Tarek [3 ]
Ammari, Samy [1 ,2 ]
机构
[1] Univ Paris Saclay, Dept Imaging, Gustave Roussy, F-94805 Villejuif, France
[2] Univ Paris Saclay, CNRS, Biomaps, INSERM,CEA,UMR1281, F-94805 Villejuif, France
[3] Univ Paris Saclay, Dept Oncol, Gustave Roussy, F-94805 Villejuif, France
关键词
PRES; chemotherapy; immunotherapy; status epilepticus; diaschisis; LEUKOENCEPHALOPATHY SYNDROME; CARBOPLATIN; IMMUNOTHERAPY;
D O I
10.3390/diagnostics12061369
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Posterior reversible encephalopathy syndrome (PRES) is a rare neurological complication that occurs following a sudden blood pressure increase. We report the case of a 64-year-old patient presenting PRES several hours after the administration of a combination of chemotherapy and a checkpoint inhibitor (carboplatin-etoposide-atezolizumab) for small-cell lung cancer. He presented consciousness disorders associated with partial epileptic seizure secondarily generalized. His arterial blood pressure was elevated and brain imaging showed multiple bilateral subcortical parietal, temporal, occipital and cerebellar T2 high signals, predominantly in the posterior region. There were no abnormal T1 signals nor bleeding but a left apparent diffusion coefficient restriction was noted. On arterial spin labelling perfusion sequences, there was an increased perfusion within the left temporo-parieto-occipital, left thalamic and right cerebellar regions. Finally, the neurological symptoms completely regressed after several days of optimal antihypertensive and antiepileptic treatment. The clinical context and radiological features, as well as the progressive resolution of the neurological symptoms, were all in favor of PRES. PRES can occur after the administration of chemotherapy and/or immunotherapy. Prompt diagnosis is crucial through a spectrum of suspicious clinical and radiological characteristics that must be rapidly recognized to quickly anticipate the optimal therapeutic strategy and avoid unnecessary complications.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Combination immunotherapy in small-cell lung cancer
    Kozuki, Toshiyuki
    ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
  • [42] The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors
    Friedlaender, Alex
    Liu, Stephen, V
    Passaro, Antonio
    Metro, Giulio
    Banna, Giuseppe
    Addeo, Alfredo
    CLINICAL LUNG CANCER, 2020, 21 (06) : E539 - E543
  • [43] Paraneoplastic Opsoclonus-myoclonus Syndrome with Anti-Hu and Anti-SOX-1 Antibodies after Immune-checkpoint Inhibitor Treatment Combined with Chemotherapy in a Patient with Small-cell Lung Cancer
    Arai, Hironori
    Utsu, Yoshikazu
    Horio, Joji
    Furukawa, Shogo
    Kikkawa, Yuriko
    INTERNAL MEDICINE, 2022, 61 (01) : 71 - 74
  • [44] Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
    Sabine Schmid
    Laetitia A. Mauti
    Alex Friedlaender
    Veronika Blum
    Sacha I. Rothschild
    Hasna Bouchaab
    Patrizia Frösch
    Christian Britschgi
    David König
    Luciano Wannesson
    Wolf-Dieter Janthur
    Sämi Schär
    Izadora Demmer
    Alfredo Addeo
    Wolfram Jochum
    Martin Früh
    Cancer Immunology, Immunotherapy, 2020, 69 : 1605 - 1613
  • [45] Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
    Schmid, Sabine
    Mauti, Laetitia A.
    Friedlaender, Alex
    Blum, Veronika
    Rothschild, Sacha I.
    Bouchaab, Hasna
    Frosch, Patrizia
    Britschgi, Christian
    Konig, David
    Wannesson, Luciano
    Janthur, Wolf-Dieter
    Schar, Sami
    Demmer, Izadora
    Addeo, Alfredo
    Jochum, Wolfram
    Fruh, Martin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (08) : 1605 - 1613
  • [46] Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy
    Riemann, Dagmar
    Turzer, Steffi
    Ganchev, Georgi
    Schuette, Wolfgang
    Seliger, Barbara
    Moeller, Miriam
    BIOMOLECULES, 2023, 13 (02)
  • [47] Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review
    Zou, Xiaomeng
    Zhou, Peng
    Lv, Wei
    Liu, Chuanyong
    Liu, Jie
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [48] Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer
    Jaime Ceballos-Viro
    José M López-Picazo
    José L Pérez-Gracia
    Jesús J Sola
    Gregorio Aisa
    Ignacio Gil-Bazo
    World Journal of Gastroenterology, 2009, 15 (18) : 2290 - 2292
  • [49] Radiotherapy with/without cisplatin following chemotherapy in limited small-cell lung cancer
    Scagliotti, GV
    Gregor, A
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3479 - 3480
  • [50] Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer
    Ceballos-Viro, Jaime
    Lopez-Picazo, Jose M.
    Perez-Gracia, Jose L.
    Sola, Jesus J.
    Aisa, Gregorio
    Gil-Bazo, Ignacio
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (18) : 2290 - 2292